Financhill
Sell
32

TECX Quote, Financials, Valuation and Earnings

Last price:
$21.48
Seasonality move :
-0.07%
Day range:
$21.08 - $22.20
52-week range:
$13.70 - $61.07
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.33x
Volume:
110.3K
Avg. volume:
184.3K
1-year change:
24.48%
Market cap:
$401.6M
Revenue:
--
EPS (TTM):
-$3.83

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
TECX
Tectonic Therapeutic
-- -- -- -50.01% $82.75
CVM
CEL-SCI
-- -- -- -- $8.00
IGC
IGC Pharma
$305K -$0.02 3.39% -50% $3.88
LCTX
Lineage Cell Therapeutics
$1.7M -$0.03 4.59% -- $3.92
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
PLX
Protalix BioTherapeutics
$21.6M -- 0.09% -- $14.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
TECX
Tectonic Therapeutic
$21.51 $82.75 $401.6M -- $0.00 0% --
CVM
CEL-SCI
$2.10 $8.00 $6.4M -- $0.00 0% --
IGC
IGC Pharma
$0.31 $3.88 $25.1M -- $0.00 0% 18.49x
LCTX
Lineage Cell Therapeutics
$0.66 $3.92 $151.8M -- $0.00 0% 14.67x
NBY
NovaBay Pharmaceuticals
$0.55 $0.85 $3.2M -- $0.00 0% 0.16x
PLX
Protalix BioTherapeutics
$1.55 $14.00 $123.4M 38.75x $0.00 0% 2.18x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
TECX
Tectonic Therapeutic
-- 4.490 -- --
CVM
CEL-SCI
-- 1.145 -- --
IGC
IGC Pharma
2.1% -0.278 0.51% 0.21x
LCTX
Lineage Cell Therapeutics
-- 0.143 -- 3.68x
NBY
NovaBay Pharmaceuticals
4.54% -0.186 1.51% 0.75x
PLX
Protalix BioTherapeutics
-- 1.057 -- 1.62x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
TECX
Tectonic Therapeutic
-- -$18.3M -- -- -- -$13.1M
CVM
CEL-SCI
-- -$6.4M -- -- -- -$4.4M
IGC
IGC Pharma
$104K -$1.9M -114.2% -116.24% -730.74% -$1.4M
LCTX
Lineage Cell Therapeutics
$1.5M -$6.5M -22.68% -22.68% -433.09% -$5M
NBY
NovaBay Pharmaceuticals
$1.6M -$2.7M -334.47% -461.38% -44% -$1.3M
PLX
Protalix BioTherapeutics
$1.9M -$4.1M 8.88% 10.9% -36.84% -$5.4M

Tectonic Therapeutic vs. Competitors

  • Which has Higher Returns TECX or CVM?

    CEL-SCI has a net margin of -- compared to Tectonic Therapeutic's net margin of --. Tectonic Therapeutic's return on equity of -- beat CEL-SCI's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    TECX
    Tectonic Therapeutic
    -- -$0.93 --
    CVM
    CEL-SCI
    -- -$2.40 --
  • What do Analysts Say About TECX or CVM?

    Tectonic Therapeutic has a consensus price target of $82.75, signalling upside risk potential of 284.71%. On the other hand CEL-SCI has an analysts' consensus of $8.00 which suggests that it could grow by 11329.71%. Given that CEL-SCI has higher upside potential than Tectonic Therapeutic, analysts believe CEL-SCI is more attractive than Tectonic Therapeutic.

    Company Buy Ratings Hold Ratings Sell Ratings
    TECX
    Tectonic Therapeutic
    4 0 0
    CVM
    CEL-SCI
    1 0 0
  • Is TECX or CVM More Risky?

    Tectonic Therapeutic has a beta of 1.636, which suggesting that the stock is 63.575% more volatile than S&P 500. In comparison CEL-SCI has a beta of 0.498, suggesting its less volatile than the S&P 500 by 50.196%.

  • Which is a Better Dividend Stock TECX or CVM?

    Tectonic Therapeutic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tectonic Therapeutic pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TECX or CVM?

    Tectonic Therapeutic quarterly revenues are --, which are smaller than CEL-SCI quarterly revenues of --. Tectonic Therapeutic's net income of -$15.9M is lower than CEL-SCI's net income of -$6.6M. Notably, Tectonic Therapeutic's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic is -- versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TECX
    Tectonic Therapeutic
    -- -- -- -$15.9M
    CVM
    CEL-SCI
    -- -- -- -$6.6M
  • Which has Higher Returns TECX or IGC?

    IGC Pharma has a net margin of -- compared to Tectonic Therapeutic's net margin of -711.67%. Tectonic Therapeutic's return on equity of -- beat IGC Pharma's return on equity of -116.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    TECX
    Tectonic Therapeutic
    -- -$0.93 --
    IGC
    IGC Pharma
    40.47% -$0.02 $6.4M
  • What do Analysts Say About TECX or IGC?

    Tectonic Therapeutic has a consensus price target of $82.75, signalling upside risk potential of 284.71%. On the other hand IGC Pharma has an analysts' consensus of $3.88 which suggests that it could grow by 1132.51%. Given that IGC Pharma has higher upside potential than Tectonic Therapeutic, analysts believe IGC Pharma is more attractive than Tectonic Therapeutic.

    Company Buy Ratings Hold Ratings Sell Ratings
    TECX
    Tectonic Therapeutic
    4 0 0
    IGC
    IGC Pharma
    2 0 0
  • Is TECX or IGC More Risky?

    Tectonic Therapeutic has a beta of 1.636, which suggesting that the stock is 63.575% more volatile than S&P 500. In comparison IGC Pharma has a beta of 1.503, suggesting its more volatile than the S&P 500 by 50.252%.

  • Which is a Better Dividend Stock TECX or IGC?

    Tectonic Therapeutic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tectonic Therapeutic pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TECX or IGC?

    Tectonic Therapeutic quarterly revenues are --, which are smaller than IGC Pharma quarterly revenues of $257K. Tectonic Therapeutic's net income of -$15.9M is lower than IGC Pharma's net income of -$1.8M. Notably, Tectonic Therapeutic's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic is -- versus 18.49x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TECX
    Tectonic Therapeutic
    -- -- -- -$15.9M
    IGC
    IGC Pharma
    18.49x -- $257K -$1.8M
  • Which has Higher Returns TECX or LCTX?

    Lineage Cell Therapeutics has a net margin of -- compared to Tectonic Therapeutic's net margin of -275.57%. Tectonic Therapeutic's return on equity of -- beat Lineage Cell Therapeutics's return on equity of -22.68%.

    Company Gross Margin Earnings Per Share Invested Capital
    TECX
    Tectonic Therapeutic
    -- -$0.93 --
    LCTX
    Lineage Cell Therapeutics
    97.6% -$0.02 $77.7M
  • What do Analysts Say About TECX or LCTX?

    Tectonic Therapeutic has a consensus price target of $82.75, signalling upside risk potential of 284.71%. On the other hand Lineage Cell Therapeutics has an analysts' consensus of $3.92 which suggests that it could grow by 489.24%. Given that Lineage Cell Therapeutics has higher upside potential than Tectonic Therapeutic, analysts believe Lineage Cell Therapeutics is more attractive than Tectonic Therapeutic.

    Company Buy Ratings Hold Ratings Sell Ratings
    TECX
    Tectonic Therapeutic
    4 0 0
    LCTX
    Lineage Cell Therapeutics
    4 1 0
  • Is TECX or LCTX More Risky?

    Tectonic Therapeutic has a beta of 1.636, which suggesting that the stock is 63.575% more volatile than S&P 500. In comparison Lineage Cell Therapeutics has a beta of 1.414, suggesting its more volatile than the S&P 500 by 41.436%.

  • Which is a Better Dividend Stock TECX or LCTX?

    Tectonic Therapeutic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lineage Cell Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tectonic Therapeutic pays -- of its earnings as a dividend. Lineage Cell Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TECX or LCTX?

    Tectonic Therapeutic quarterly revenues are --, which are smaller than Lineage Cell Therapeutics quarterly revenues of $1.5M. Tectonic Therapeutic's net income of -$15.9M is lower than Lineage Cell Therapeutics's net income of -$4.1M. Notably, Tectonic Therapeutic's price-to-earnings ratio is -- while Lineage Cell Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic is -- versus 14.67x for Lineage Cell Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TECX
    Tectonic Therapeutic
    -- -- -- -$15.9M
    LCTX
    Lineage Cell Therapeutics
    14.67x -- $1.5M -$4.1M
  • Which has Higher Returns TECX or NBY?

    NovaBay Pharmaceuticals has a net margin of -- compared to Tectonic Therapeutic's net margin of -49.65%. Tectonic Therapeutic's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    TECX
    Tectonic Therapeutic
    -- -$0.93 --
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
  • What do Analysts Say About TECX or NBY?

    Tectonic Therapeutic has a consensus price target of $82.75, signalling upside risk potential of 284.71%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 54.55%. Given that Tectonic Therapeutic has higher upside potential than NovaBay Pharmaceuticals, analysts believe Tectonic Therapeutic is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    TECX
    Tectonic Therapeutic
    4 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is TECX or NBY More Risky?

    Tectonic Therapeutic has a beta of 1.636, which suggesting that the stock is 63.575% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

  • Which is a Better Dividend Stock TECX or NBY?

    Tectonic Therapeutic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tectonic Therapeutic pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TECX or NBY?

    Tectonic Therapeutic quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Tectonic Therapeutic's net income of -$15.9M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Tectonic Therapeutic's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TECX
    Tectonic Therapeutic
    -- -- -- -$15.9M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
  • Which has Higher Returns TECX or PLX?

    Protalix BioTherapeutics has a net margin of -- compared to Tectonic Therapeutic's net margin of -35.79%. Tectonic Therapeutic's return on equity of -- beat Protalix BioTherapeutics's return on equity of 10.9%.

    Company Gross Margin Earnings Per Share Invested Capital
    TECX
    Tectonic Therapeutic
    -- -$0.93 --
    PLX
    Protalix BioTherapeutics
    19.11% -$0.05 $45.2M
  • What do Analysts Say About TECX or PLX?

    Tectonic Therapeutic has a consensus price target of $82.75, signalling upside risk potential of 284.71%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.00 which suggests that it could grow by 803.23%. Given that Protalix BioTherapeutics has higher upside potential than Tectonic Therapeutic, analysts believe Protalix BioTherapeutics is more attractive than Tectonic Therapeutic.

    Company Buy Ratings Hold Ratings Sell Ratings
    TECX
    Tectonic Therapeutic
    4 0 0
    PLX
    Protalix BioTherapeutics
    0 0 0
  • Is TECX or PLX More Risky?

    Tectonic Therapeutic has a beta of 1.636, which suggesting that the stock is 63.575% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of -0.048, suggesting its less volatile than the S&P 500 by 104.824%.

  • Which is a Better Dividend Stock TECX or PLX?

    Tectonic Therapeutic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tectonic Therapeutic pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TECX or PLX?

    Tectonic Therapeutic quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $10.1M. Tectonic Therapeutic's net income of -$15.9M is lower than Protalix BioTherapeutics's net income of -$3.6M. Notably, Tectonic Therapeutic's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 38.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic is -- versus 2.18x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TECX
    Tectonic Therapeutic
    -- -- -- -$15.9M
    PLX
    Protalix BioTherapeutics
    2.18x 38.75x $10.1M -$3.6M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Salesforce Stock Be in 5 Years?
Where Will Salesforce Stock Be in 5 Years?

Salesforce (NYSE: CRM) just turned in a quarter that, on…

2 Ultra Safe Dividend Stocks to Buy Now
2 Ultra Safe Dividend Stocks to Buy Now

Historically, blue-chip dividend stocks have been good choices for periods…

Where Will Asana Stock Be in 5 Years?
Where Will Asana Stock Be in 5 Years?

Asana stock hasn’t given many investors on Wall Street any…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Sell
31
REGN alert for May 31

Regeneron Pharmaceuticals [REGN] is down 19.04% over the past day.

Buy
55
RGC alert for May 31

Regencell Bioscience Holdings [RGC] is up 16.13% over the past day.

Sell
42
AMBA alert for May 31

Ambarella [AMBA] is down 15.13% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock